Supplementary Table 1. Patient demographics and baseline characteristics (treated patients).

Similar documents
Supplementary Appendix

JARDIAMET. (empagliflozin and metformin hydrochloride) 5 mg/500 mg, 5 mg/850 mg, 5 mg/1000 mg, 12.5 mg/500 mg, 12.5 mg/850 mg, 12.

Supplementary Online Content

Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic

Supplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures

egfr > 50 (n = 13,916)

Deprivation Study. The Freiburg Study

Supplementary Data. Formula S1. Calculation of IG fluctuation from continuous glucose monitoring profiles Z T 1 T

SUPPLEMENTARY DATA. Supplementary Table S1. Clinical characteristics of the study subjects.*

Clinical Trial Results Disclosure Synopsis

SITA 100 mg (n = 378)

JARDIANCE. empagliflozin

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SYNOPSIS 2/198 CSR_BDY-EFC5825-EN-E02. Name of company: TABULAR FORMAT (For National Authority Use only)

Statistical Analysis Plan FINAL. DexComG4 (DexCom Corporation) CGMMDI GOLD-Study

High intensity exercise improves cardiac structure and function and reduces liver fat in adults with Type 2 diabetes

TRANSPARENCY COMMITTEE

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.

EmpagliflozinasAdd-Onto MetformininPatientsWithType 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial DOI: 10.

Sponsor Novartis. Generic Drug Name Vildagliptin/Metformin. Therapeutic Area of Trial Type 2 diabetes. Approved Indication Type 2 diabetes

Supplementary Online Content

GLYXAMBI. (empagliflozin and linagliptin) 10 mg/5 mg, 25 mg/5 mg

Medical therapy advances London/Manchester RCP February/June 2016

Case study: Lean adult with no complications, newly diagnosed with type 2 diabetes

Brand name: Steglatro. Generic name: Ertugliflozin (er too gli FLOE zin) Manufacturer: Merck

Depok-Indonesia STEPS Survey 2003

Metabolic Syndrome and Chronic Kidney Disease

Supplementary Appendix

Oral Agents. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

AUSTRALIAN PRODUCT INFORMATION GLYXAMBI empagliflozin and linagliptin filmcoated

Nature Medicine: doi: /nm.3891

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

The role of physical activity in the prevention and management of hypertension and obesity

Know Your Number Aggregate Report Single Analysis Compared to National Averages

Supplementary Online Content

Clinical Trial Synopsis TL-OPI-518, NCT#

ASSeSSing the risk of fatal cardiovascular disease

Clinical Study Synopsis

Allopurinol reduces left ventricular hypertrophy and endothelial dysfunction in patients with chronic kidney disease

Diabetes and Hypertension

S150 KEEP Analytical Methods. American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153

Association between arterial stiffness and cardiovascular risk factors in a pediatric population

AUSTRALIAN PRODUCT INFORMATION - JARDIANCE empagliflozin film-coated tablets

Diabetes and New Meds for Cardiovascular Risk Reduction. F. Dwight Chrisman, MD, FACC. Disclosures: BI Boehringer Ingelheim speaker

Supplementary Material. Serum Chloride is an Independent Predictor of Mortality in Hypertensive Patients

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)

Supplementary Information for: Predictors of chronic kidney disease in type 1 diabetes: a longitudinal study from the AMD Annals initiative.

Chemistry Reference Ranges and Critical Values

Supplementary Table 1. Criteria for selection of normal control individuals among healthy volunteers

Chemistry Reference Ranges and Critical Values

Clinical Trial Synopsis TL-OPI-525, NCT#

Effects of Lowering LDL Cholesterol on Progression of Kidney Disease

Early treatment for patients with Type 2 Diabetes

Safety profile of Liraglutide: Recent Updates. Mohammadreza Rostamzadeh,M.D.

Variability in drug response: towards more personalized diabetes care Petrykiv, Sergei

Data Analysis Plan for assessing clinical efficacy and safety of ER niacin/laropiprant in the HPS2-THRIVE trial

Systolic Blood Pressure Intervention Trial (SPRINT)

Have you seen a patient like Elaine *?

Adult Diabetes Clinician Guide NOVEMBER 2017

PROTEZIONE DAL DANNO RENALE NEL DIABETE TIPO 2: RUOLO DEI NUOVI FARMACI. Massimo Boemi UOC Malattie Metaboliche e Diabetologia IRCCS INRCA Ancona

Heart Outcomes Prevention Evaluation (HOPE) - 3 Combined Lipid Lowering and Blood Pressure Lowering in Moderate Risk People

DISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE

Obesity Prevention and Control: Provider Education with Patient Intervention

Non-insulin treatment in Type 1 DM Sang Yong Kim

Galvus the most comprehensively studied DPP-4 inhibitor

Have you seen a patient like Carol *?

Analytical Methods: the Kidney Early Evaluation Program (KEEP) The Kidney Early Evaluation program (KEEP) is a free, community based health

Lilly Diabetes: Pipeline Update

A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

New Hypertension Guidelines. Kofi Osei, MD

Hypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital

Jared Moore, MD, FACP

The ABCs (A1C, BP and Cholesterol) of Diabetes

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Tables of Normal Values (As of February 2005)

Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension

CATHETER-BASED RENAL DENERVATION INCREASES INSULIN SENSITIVITY AND IMPROVES GLUCOSE METABOLISM IN PATIENTS WITH RESISTANT HYPERTENSION

CHALLENGING CASE PRESENTATION Steroid Induced Hyperglycemia

Prevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan

Efficacy of Body Weight Reduction on the SGLT2 Inhibitor in People with Type 2 Diabetes Mellitus

Supplementary Appendix

Supplementary Online Content

Challenges in type 2 diabetes control: slipping control and weight gain

DIABETES AND LABORATORY TESTS. Author: Josephine Davis

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu

Supplementary Appendix

RISK FACTORS OR COMPLICATIONS AND RECOMMENDED TREATMENT GOALS AND FREQUENCY OF EVALUATION FOR ADULTS WITH DIABETES

Type 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice.

ROTUNDA HOSPITAL DEPARTMENT OF LABORATORY MEDICINE

New Hypertension Guideline Recommendations for Adults July 7, :45-9:30am

Clinical Study Synopsis

SMJ Singapore Medical Journal

LEADER Liraglutide and cardiovascular outcomes in type 2 diabetes

Multiple Factors Should Be Considered When Setting a Glycemic Goal

Using the New Hypertension Guidelines

Transcription:

Supplementary Table 1. Patient demographics and baseline characteristics (treated patients). Placebo (n=188) 10 mg (n=186) 25 mg (n=189) Total (n=563) Gender, n (%) Male 75 (40) 97 (52) 84 (44) 256 (45) Female 113 (60) 89 (48) 105 (56) 307 (55) Age (years) 55.3 ± 10.1 56.7 ± 8.7 58.0 ± 9.4 56.7 ± 9.5 Race, n (%) White 174 (93) 175 (94) 182 (96) 531 (94) Black/African-American 8 (4) 7 (4) 4 (2) 19 (3) Other 6 (3) 4 (2) 3 (2) 13 (2) Time since diagnosis of type 2 diabetes, n (%) 1 year 1 (1) 0 0 1 (<1) >1 to 5 years 17 (9) 22 (12) 11 (6) 50 (9) >5 to 10 years 40 (21) 44 (24) 38 (20) 122 (22) >10 years 130 (69) 120 (65) 140 (74) 390 (69) Body weight (kg) 95.5 ±17.5 96.7 ± 17.9 95.9 ± 17.3 96.0 ± 17.5 Body mass index (kg/m 2 ) 34.7 ± 4.3 34.7 ± 3.8 35.0 ± 4.0 34.8 ± 4.1 HbA 1c (%) 8.33 ± 0.72 8.39 ± 0.74 8.29 ± 0.72 8.34 ± 0.73 HbA 1c (mmol/mol) 68 ± 7.9 68 ± 8.1 67 ± 7.9 68 ± 8.0 Fasting plasma glucose (mmol/l) 8.41 ± 2.54 8.83 ± 2.66 8.34 ± 2.70 8.52 ± 2.64 Systolic blood pressure (mmhg) 132.6 ± 15.8 134.2 ± 16.4 132.9 ± 14.2 133.3 ± 15.5 Diastolic blood pressure (mmhg) 78.2 ± 8.8 79.5 ± 8.5 78.7 ± 8.5 78.8 ± 8.6 egfr (ml/min/1.73 m 2 [MDRD equation]) 83.4 ± 15.4 84.1 ± 17.8 84.4 ± 16.6 84.0 ± 16.6 Antidiabetes background medication, n (%) Metformin and insulin 135 (72) 128 (69) 137 (72) 400 (71) Insulin only 53 (28) 58 (31) 52 (28) 163 (29) Insulin dose (IU/day) 93.1 ± 48.6 89.9 ± 38.0 92.9 ± 45.8 92.0 ± 44.3 Insulin dose (IU/kg) 1.0 ± 0.4 0.9 ± 0.4 1.0 ± 0.4 1.0 ± 0.4 Basal (IU/day) 52.7 ± 31.6 49.3 ± 23.2 50.8 ± 25.0 Basal (IU/kg) 0.6 ± 0.3 0.5 ± 0.2 0.5 ± 0.3 Prandial (IU/day) 39.6 ± 29.1 40.0 ± 28.6 41.2 ± 34.9 Prandial (IU/kg) 0.4 ± 0.3 0.4 ± 0.3 0.4 ± 0.3 Number of prandial shots 2.6 ± 0.7 2.7 ± 0.6 2.6 ± 0.8 Number of prandial shots per day, n (%) 0 2 (1) 0 4 (2) 6 (1)

1 12 (6) 12 (6) 12 (6) 36 (6) 2 44 (23) 34 (18) 37 (20) 115 (20) 3 120 (64) 133 (72) 128 (68) 381 (68) 4 8 (4) 3 (2) 6 (3) 17 (3) Metformin dose (mg/day) 2023 ± 586 1977 ± 527 2077 ± 511 2027 ± 542 1500 mg, n (%*) 121 (90) 118 (92) 131 (96) 370 (93) <1500 mg, n (%*) 14 (10) 10 (8) 6 (4) 30 (8) Data are mean ± SD unless otherwise indicated. *Percentage of patients receiving metformin. MDRD, Modification of Diet in Renal Disease. IU, international units.

Supplementary Table 2. Summary of changes in blood pressure. Placebo 10 mg 25 mg SBP at baseline (mmhg) 132.6 ± 1.2 134.2 ± 1.2 132.9 ± 1.0 SBP at week 18 (mmhg) 131.7 ± 1.1 130.2 ± 1.1 130.3 ± 1.0 Change from baseline in SBP (mmhg) -1.2 ± 0.8-3.6 ± 0.8-2.9 ± 0.8 Difference vs. placebo (95% confidence interval); P value -2.4 ± 1.2 (-4.7, -0.2); 0.037-1.7 ± 1.1 (-3.9, 0.6); 0.141 SBP at week 52 (mmhg) 130.1 ± 1.3 130.8 ± 1.2 129.0 ± 1.3 Change from baseline in SBP (mmhg) -2.9 ± 1.0-3.4 ± 1.0-3.8 ± 1.0 Difference vs. placebo (95% confidence interval); P value -0.6 ± 1.4 (-3.4, 2.3); 0.700-0.9 ± 1.4 (-3.7, 1.9); 0.531 DBP at baseline (mmhg) 78.2 ± 0.6 79.5 ± 0.6 78.7 ± 0.6 DBP at week 18 (mmhg) 78.2 ± 0.5 78.0 ± 0.7 77.8 ± 0.6 Change from baseline in DBP (mmhg) -0.3 ± 0.5-1.2 ± 0.5-1.0 ± 0.5 Difference vs. placebo (95% confidence interval); P value -1.0 ± 0.7 (-2.4, 0.4); 0.179-0.7 ± 0.7 (-2.1, 0.7); 0.310 DBP at week 52 (mmhg) 78.0 ± 0.7 77.9 ± 0.8 76.6 ± 0.8 Change from baseline in DBP (mmhg) -0.5 ± 0.6-1.2 ± 0.6-2.5 ± 0.6 Difference vs. placebo (95% confidence interval); P value -0.7 ± 0.9 (-2.4, 1.1); 0.464-1.9 ± 0.9 (-3.7, -0.1); 0.035 Data are mean ± SE except for change from baseline values and difference vs. placebo, which are adjusted mean ± SE. SBP and DBP at week 18: ANCOVA in FAS using LOCF. SBP and DBP at week 52: ANCOVA in PPS-completers-52 using LOCF. PPS-completers-52: patients in the FAS who were on treatment up to day 357 and did not have important protocol violations.

Supplementary Table 3. Laboratory measurements. Baseline Placebo Change from baseline 10 mg Change from Baseline baseline 25 mg Change from Baseline baseline Hematocrit (%)* 42.6 ± 5.8 0.7 ± 4.1 41.8 ±5.3 4.8 ± 4.1 43.1 ± 5.4 4.4 ± 4.1 Follow-up 41.4 ± 4.4 0.7 ± 2.9 41.4 ± 4.1 2.0 ± 2.8 41.9 ± 3.8 1.7 ± 2.7 Uric acid (μmol/l)* 326 ± 121 12 ± 81 326 ± 127-23 ± 95 331 ± 123-42 ± 92 egfr (ml/min/1.73m 2 [MDRD]) 83.4 ± 5.4-2.0 ± 11.4 84.1 ± 17.8-1.6 ± 11.5 84.4 ± 16.6-1.6 ± 11.3 Follow-up 82.4 ± 5.0-0.9 ± 11.5 83.9 ± 17.6 2.4 ± 13.0 83.8 ± 15.8 0.9 ± 11.8 Electrolytes (mmol/l)* Sodium 141 ± 2 1 ± 2 141 ± 2 1 ± 2 141 ± 2 1 ± 2 Potassium 4.2 ± 0.3 0.1 ± 0.3 4.2 ± 0.3 0.0 ± 0.4 4.2 ± 0.3 0.0 ± 0.3 Calcium 9.8 ± 0.4-0.1 ± 0.4 9.8 ± 0.4-0.1 ± 0.4 9.8 ± 0.4-0.1 ± 0.3 Magnesium 1.8 ± 0.2-0.0 ± 0.1 1.8 ± 0.2 0.1 ± 0.1 1.8 ± 0.2 0.1 ± 0.2 Phosphate 3.7 ± 0.3 0.0 ± 0.3 3.7 ± 0.3 0.1 ± 0.3 3.7 ± 0.3 0.1 ± 0.3 Total cholesterol (mmol/l) 4.79 ± 0.09 0.10 ± 0.06 4.70 ± 0.09 0.05 ± 0.06 4.78 ± 0.09 0.06± 0.06 Difference vs. placebo -0.05 ± 0.08-0.04 ± 0.08 P value 0.523 0.642 Follow-up 4.79 ± 0.10 0.02 ± 0.09 4.71 ± 0.11 0.07 ± 0.08 4.78 ± 0.09 0.14 ±0.07 HDL-cholesterol (mmol/l) 1.17 ± 0.02-0.02 ± 0.01 1.19 ± 0.02 0.01 ± 0.01 1.20 ± 0.02 0.01 ± 0.01 Difference vs. placebo 0.03 ± 0.02 0.03 ± 0.02 P value 0.088 0.085 Follow-up 1.17 ± 0.02-0.03 ± 0.02 1.20 ± 0.03 0.00 ± 0.01 1.20 ± 0.03 0.03 ± 0.02 LDL-cholesterol (mmol/l) 2.73 ± 0.08 0.12 ± 0.05 2.68 ± 0.08-0.06 ± 0.05 2.71 ± 0.07 0.06 ± 0.05 Difference vs. placebo -0.18 ± 0.07-0.06 ± 0.07 P value 0.012 0.391 Follow-up 2.73 ± 0.08 0.05 ± 0.07 2.67 ± 0.09-0.02 ± 0.07 2.70 ± 0.08 0.12 ± 0.06 Triglycerides (mmol/l) 2.02 ± 0.14 0.01 ± 0.10 1.94 ± 0.10 0.20 ± 0.10 1.92 ± 0.08-0.03 ± 0.10 Difference vs. placebo 0.19 ± 0.14-0.04 ± 0.14 P value 0.191 0.793 Follow-up 2.03 ± 0.16 0.03 ± 0.10 1.93 ± 0.11 0.13 ± 0.09 1.90 ± 0.09 0.01 ± 0.08 Data are mean ± SD in treated set, unless otherwise indicated. Changes from baseline are last value on treatment unless otherwise stated. *Normalized to standard reference range. Patients in FAS with data available 3-6 weeks after last dose of study medication based on observed results. Baseline data are mean ± SE, change from baseline data are adjusted mean ± SE based on ANCOVA using LOCF including values on rescue medication; data are week 52 except for follow-up.

Supplementary Figure 1. Study flow.

Supplementary Figure 2. Effect of empagliflozin on FPG. (A) Change from baseline in FPG at week 18 (ANCOVA, full analysis set [FAS], last observation carried forward [LOCF] imputation at week 18; (B) change from baseline in FPG at week 52 (ANCOVA, PPS-completers-52, LOCF]. Data are mean±se at baseline and adjusted mean±se on treatment. PPS-completers- 52 set: patients who were on treatment up to day 357 and did not have important protocol violations. Blue bars = MDI insulin + placebo; purple bars = MDI insulin + empagliflozin 10 mg; green bars = MDI insulin + empagliflozin 25 mg.

Supplementary Figure 3. Effect of empagliflozin on blood pressure. (A) Change from baseline in SBP at week 18 (ANCOVA, full analysis set [FAS], last observation carried forward [LOCF]); (B) change from baseline in DBP at week 18 (ANCOVA, FAS, LOCF); (C) change from baseline in SBP at week 52 (ANCOVA, PPS-completers-52, LOCF); (D) change from baseline in DBP at week 52 (ANCOVA, PPS-completers-52, LOCF). Data are mean±se at baseline and adjusted mean±se on treatment. PPScompleters-52 set: patients who were on treatment up to day 357 and did not have important protocol violations. Blue bars = MDI insulin + placebo; purple bars = MDI insulin + empagliflozin 10 mg; green bars = MDI insulin + empagliflozin 25 mg.